Introduction
Results
PRMT1 methylates cGAS and suppresses cGAS/STING signaling in cancer cells
a
Genetic ablation or pharmaceutic inhibition of PRMT1 leads to activation of cGAS/STING signaling
a
PRMT1 methylates cGAS at the conserved Arg133 residue on its N-terminus
a
PRMT1 suppresses tumor immunity in a cGAS-dependent manner
a
Pharmaceutic inhibition of PRMT1 triggers tumor immunity in a cGAS-dependent manner in vitro and in vivo
a
PRMT1 ablation increases PD-L1 expression in a cGAS-dependent manner
a
PRMT1 inhibitor synergizes with anti-PD-1 antibody to boost anti-tumor immunity
a